Acrotech launches ADQUEY in U.S., sets up dermatology unit
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo's U.S. subsidiary Acrotech Biopharma has launched ADQUEY (difamilast 1%) ointment in the United States for treating mild-to-moderate atopic dermatitis in adults and children aged 2 and above. The product was discovered by Otsuka Pharmaceutical and licensed to Acrotech for U.S. commercialization. A dedicated dermatology division has been set up to support the launch and future products. Target market estimated at about US$ 1.3 billion per IQVIA MAT data ending July 2026.
Marks Aurobindo's entry into the U.S. dermatology market through subsidiary Acrotech. Positive pipeline and specialty growth signal; revenue contribution unclear at launch.